Invacare (NYSE:IVC) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Sunday.
Several other equities analysts also recently commented on IVC. KeyCorp reiterated a “buy” rating and set a $18.00 price target on shares of Invacare in a report on Friday, November 10th. Zacks Investment Research downgraded Invacare from a “hold” rating to a “sell” rating in a report on Tuesday, November 14th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $16.00.
Invacare (IVC) opened at $16.85 on Friday. Invacare has a twelve month low of $9.90 and a twelve month high of $17.95. The company has a market capitalization of $660.30, a P/E ratio of -7.17 and a beta of 2.45. The company has a quick ratio of 1.57, a current ratio of 2.28 and a debt-to-equity ratio of 0.55.
Invacare (NYSE:IVC) last released its quarterly earnings data on Tuesday, November 7th. The health services provider reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.02. Invacare had a negative return on equity of 13.33% and a negative net margin of 7.95%. The firm had revenue of $250.91 million for the quarter, compared to the consensus estimate of $239.88 million. During the same quarter in the prior year, the company posted ($0.37) earnings per share. The firm’s revenue was down 6.4% on a year-over-year basis. analysts expect that Invacare will post -2.12 EPS for the current fiscal year.
A number of hedge funds have recently made changes to their positions in IVC. Vanguard Group Inc. boosted its position in shares of Invacare by 3.8% in the second quarter. Vanguard Group Inc. now owns 2,934,593 shares of the health services provider’s stock valued at $38,736,000 after acquiring an additional 107,359 shares during the period. Barrow Hanley Mewhinney & Strauss LLC boosted its position in shares of Invacare by 654.1% in the third quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 2,383,222 shares of the health services provider’s stock valued at $37,535,000 after acquiring an additional 2,067,186 shares during the period. Royce & Associates LP boosted its position in shares of Invacare by 4.4% in the third quarter. Royce & Associates LP now owns 1,414,169 shares of the health services provider’s stock valued at $22,273,000 after acquiring an additional 59,430 shares during the period. Northpointe Capital LLC boosted its position in shares of Invacare by 96.8% in the third quarter. Northpointe Capital LLC now owns 1,151,700 shares of the health services provider’s stock valued at $18,139,000 after acquiring an additional 566,574 shares during the period. Finally, Elk Creek Partners LLC boosted its position in shares of Invacare by 17.5% in the third quarter. Elk Creek Partners LLC now owns 869,081 shares of the health services provider’s stock valued at $13,688,000 after acquiring an additional 129,676 shares during the period. Institutional investors own 94.65% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/02/valuengine-upgrades-invacare-ivc-to-hold.html.
Invacare Corporation is a manufacturer and distributor for medical equipment used in non-acute care settings. The Company’s geographical segments are Europe; North America, which includes North America/Home Medical Equipment (North America/HME) and Institutional Products Group (IPG) segments, and Asia/Pacific.
Receive News & Ratings for Invacare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invacare and related companies with MarketBeat.com's FREE daily email newsletter.